High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage
Open Access
- 1 January 2020
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
Abstract
Conventional treatments for follicular thyroid cancer (FTC) can be ineffective, leading to poor prognosis. The aim of this study was to identify mutations associated with FTC that would serve as novel molecular markers of the disease and its outcome and could potentially identify new therapeutic targets. FLT3 mutations were first detected in a 29-year-old White female diagnosed with metastasized, treatment-refractory FTC. Analyses of FLT3 mutational status through next-generation sequencing of formalin-fixed, paraffin-embedded FTC specimens were subsequently performed in 35 randomly selected patients diagnosed with FTC. FLT3 mutations were found in 69% of patients. FLT3 mutation-positive patients were significantly older than those that were FLT3 mutation-negative [median age at diagnosis 54 (36–82) versus 45 (27–58) (p = 0.023)]. Patients over 60 years were 23 times more likely to be FLT3 mutation-positive (p = 0.006). However, the number of FLT3 mutations did not correlate with age (r-Pearson: –0.244, p-value: 0.25). A total of 26 mutations were identified in the FLT3 gene with 2–16 FLT3 mutations in each FLT3 mutation-positive patient (mean: 5.6 mutations/patient). Tyrosine kinase domain (TKD) mutations in the FLT3 gene were detected in 58% of FLT3 mutation-positive patients. All FLT3 mutation-positive patients with a disease stage of pT2N1 or worse harbored at least one mutation in the TKD of FLT3. There is a wide spectrum and high frequency of FLT3 mutations in FTC. The precise role of FLT3 mutations in the genesis of FTC, as well as its potential role as a therapeutic target, requires further investigation.This publication has 50 references indexed in Scilit:
- Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted SequencingiScience, 2019
- Integrating mutation variant allele frequency into clinical practice in myeloid malignanciesHematology/Oncology and Stem Cell Therapy, 2016
- Systematic Evaluation of Sanger Validation of Next-Generation Sequencing VariantsClinical Chemistry, 2016
- Cabozantinib in Thyroid CancerRecent Patents on Anti-Cancer Drug Discovery, 2015
- Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger SequencingThe Journal of Molecular Diagnostics, 2015
- DNA sequencing – spanning the generationsNew Biotechnology, 2013
- Targeted Next-Generation Sequencing can Replace Sanger Sequencing in Clinical DiagnosticsHuman Mutation, 2013
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutationBlood, 2012
- SIFT: predicting amino acid changes that affect protein functionNucleic Acids Research, 2003
- Prognostic significance of FLT3 ITD and D835 mutations in AML patientsThe Hematology Journal, 2003